| A cellular microRNA mediates antiviral defense in human cells CH Lecellier, P Dunoyer, K Arar, J Lehmann-Che, S Eyquem, C Himber, ... Science 308 (5721), 557-560, 2005 | 1197 | 2005 |
| Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer D Groheux, S Giacchetti, JL Moretti, R Porcher, M Espié, J Lehmann-Che, ... European journal of nuclear medicine and molecular imaging 38, 426-435, 2011 | 433 | 2011 |
| A refined molecular taxonomy of breast cancer M Guedj, L Marisa, A De Reynies, B Orsetti, R Schiappa, F Bibeau, ... Oncogene 31 (9), 1196-1206, 2012 | 329 | 2012 |
| p53 in breast cancer subtypes and new insights into response to chemotherapy P Bertheau, J Lehmann-Che, M Varna, A Dumay, B Poirot, R Porcher, ... The Breast 22, S27-S29, 2013 | 267 | 2013 |
| Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des … T Cluzeau, M Sebert, R Rahmé, S Cuzzubbo, J Lehmann-Che, ... Journal of Clinical Oncology 39 (14), 1575-1583, 2021 | 218 | 2021 |
| Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen P Bertheau, E Turpin, DS Rickman, M Espié, A De Reynies, JP Feugeas, ... PLoS medicine 4 (3), e90, 2007 | 211 | 2007 |
| High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors E Manié, A Vincent-Salomon, J Lehmann-Che, G Pierron, E Turpin, ... Cancer research 69 (2), 663-671, 2009 | 196 | 2009 |
| Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine C Bally, L Adès, A Renneville, M Sebert, V Eclache, C Preudhomme, ... Leukemia research 38 (7), 751-755, 2014 | 178 | 2014 |
| Distinct tumor protein p53 mutants in breast cancer subgroups A Dumay, JP Feugeas, E Wittmer, J Lehmann‐Che, P Bertheau, M Espié, ... International journal of cancer 132 (5), 1227-1231, 2013 | 147 | 2013 |
| Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma H Janouskova, A Maglott, DY Leger, C Bossert, F Noulet, E Guerin, ... Cancer research 72 (14), 3463-3470, 2012 | 134 | 2012 |
| Hereditary renal cancer syndromes: an update of a systematic review J Verine, A Pluvinage, G Bousquet, J Lehmann-Che, C De Bazelaire, ... European urology 58 (5), 701-710, 2010 | 132 | 2010 |
| Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15 J Lehmann-Che, AS Hamy, R Porcher, M Barritault, F Bouhidel, ... Breast Cancer Research 15, 1-11, 2013 | 125 | 2013 |
| Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia N Maslah, N Salomao, L Drevon, E Verger, N Partouche, P Ly, P Aubin, ... Haematologica 105 (6), 1539, 2020 | 120 | 2020 |
| Prognostic biomarkers used for localised prostate cancer management: a systematic review PJ Lamy, Y Allory, AS Gauchez, B Asselain, P Beuzeboc, P De Cremoux, ... European Urology Focus 4 (6), 790-803, 2018 | 109 | 2018 |
| Molecular and functional MDR1‐Pgp and MRPs expression in human glioblastoma multiforme cell lines X Declèves, A Fajac, J Lehmann‐Che, M Tardy, C Mercier, I Hurbain, ... International journal of cancer 98 (2), 173-180, 2002 | 106 | 2002 |
| Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab M Cizkova, ME Dujaric, J Lehmann-Che, V Scott, O Tembo, B Asselain, ... British journal of cancer 108 (9), 1807-1809, 2013 | 104 | 2013 |
| Foamy viruses—a world apart O Delelis, J Lehmann-Che, A Saïb Current opinion in microbiology 7 (4), 400-406, 2004 | 99 | 2004 |
| Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice B Leroy, ML Ballinger, F Baran-Marszak, GL Bond, A Braithwaite, ... Cancer research 77 (6), 1250-1260, 2017 | 96 | 2017 |
| Chromatin tethering of incoming foamy virus by the structural Gag protein J Tobaly‐Tapiero, P Bittoun, J Lehmann‐Che, O Delelis, ML Giron, ... Traffic 9 (10), 1717-1727, 2008 | 93 | 2008 |
| IDH-mutation is a weak predictor of long-term survival in glioblastoma patients A Amelot, P De Cremoux, V Quillien, M Polivka, H Adle-Biassette, ... PloS one 10 (7), e0130596, 2015 | 85 | 2015 |
